Development of a Visio-behavioral Scale to Evaluate Visual Abilities of Patients With Profound Multiple Intellectual Disabilities (PLH-Vision) (PLH-Vision)

September 22, 2021 updated by: Assistance Publique - Hôpitaux de Paris

The main objective of this study is to develop and validate a visio-behavioral scale of visual abilities for subjects with profound multiple intellectual disabilities.

The secondary objectives of the study are:

  • to validate the structure of the scale.
  • to evaluate the reproducibility of scale with the intra- and inter-examiners, and the influence of the different professions of examiners.
  • to evaluate the feasibility of visio-behavioral scale.
  • to evaluate the sensitivity to change.
  • to study the uniformity of use of the scale depending on the type of patients (age, disability level, pathology).
  • to study the prevalence of the visual disorder in profound multiple intellectual disabilities subjects.

Study Overview

Detailed Description

This study includes 3 phases:

  • Elaboration of a list of behavioral items by a group of multi-disciplinary expertise (physicians, nurses, caregivers, ophthalmologies, orthoptists) based on their clinical experiences.
  • Development of the scale based on the sample obtained by a prospective multicenter research trial.
  • Validation of the sample obtained by a prospective transversal multicenter study.

This study will be performed in 5 centers in France. The enrollment of patients planned for 24 months targeting 310 patients. The duration of follow-up of the study for each patient will be varied according to the group of patients, il will be 1 day for group 1, 2 weeks for group 2, or 6 months for group 3.

Study Type

Observational

Enrollment (Actual)

232

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Var
      • Hyères, Var, France, 83407
        • Hôpital San Salvadour

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

3 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Profound multiple intellectual disabilities patients aged 3 years or older.

Description

Inclusion Criteria:

  • Causal brain injury occurred before the age of 3 years.
  • Severe or deep mental retardation as defined by DSM IV.
  • Motor impairment: para / tetraparesis, hemiparesis, ataxia, or extrapyramidal motor disorders.
  • Score of Gross Motor Function Classification System [Palisano 1997] is III, IV or V.
  • Score of Functional Independence Measure < 55.
  • Subject aged ≥3 years (because the visio-behavioral scale is not adapted for children younger than 3 years).
  • Beneficiary of a social protection.
  • Written consent signed by guardian or legal representative, or parents in case of a minor subject.

Exclusion Criteria:

  • Acute intercurrent pathology precluding examinations.
  • Patient with hypersensitivity to tropicamide, atropine or benzalkonium chloride.
  • Angle closure glaucoma suspect patient.
  • Patient with severe hypertension.
  • Short life expectancy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Group 1
The duration of follow-up of group 1 in the study is 1 day.
To perform the classification with the scale by caregiver.
To perform the classification with the scale by orthoptist at the end of 2 weeks
To perform the classification with the scale by orthoptist at the end 6 months.
Group 2
The duration of follow-up of group 2 in the study is 2 weeks.
To perform the classification with the scale by orthoptist at the end of 2 weeks
To perform the classification with the scale by orthoptist at the end 6 months.
Group 3
The duration of follow-up of group 3 in the study is 6 months.
To perform the classification with the scale by orthoptist at the end 6 months.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Concordance of classification
Time Frame: throughout the study: 31 months
Statistical analysis: concordance between the classification obtained by caregiver with the scale, and the classification obtained by orthoptist-ophthalmology.
throughout the study: 31 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Structure of the scale
Time Frame: throughout the study: 31 months
Statistical analysis to validate the structure of the scale.
throughout the study: 31 months
Reproducibility of scale
Time Frame: throughout the study: 31 months
Statistical analysis to evaluate the reproducibility of scale with the intra- and inter-examiners, and the influence of the different professions of examiners.
throughout the study: 31 months
Feasibility of visio-behavioral scale
Time Frame: throughout the study: 31 months

Statistical analysis to evaluate by the proportion of patients who have the complet examination, the average of time to all examens, the tolerance data.

feasibility of visio-behavioral scale.

throughout the study: 31 months
Sensitivity to change
Time Frame: throughout the study: 31 months
Statistical analysis to evaluate the sensitivity to change.
throughout the study: 31 months
Uniformity of use of the scale
Time Frame: throughout the study: 31 months
Statistical analysis to assess the uniformity of use of the scale depending on the type of patients (age, disability level, pathology).
throughout the study: 31 months
Prevalence of the visual disorder
Time Frame: throughout the study: 31 months
Statistical analysis to study the prevalence of the visual disorder in profound multiple intellectual disabilities subjects.
throughout the study: 31 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Marie-Christine ROUSSEAU, MD, AP-HP, Hôpital San Salvadour, 83407 Hyères
  • Study Chair: Soizic CHARBONNIER, Orthoptist, Cabinet du Lycée

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 20, 2017

Primary Completion (Actual)

April 13, 2021

Study Completion (Actual)

April 13, 2021

Study Registration Dates

First Submitted

December 12, 2016

First Submitted That Met QC Criteria

January 31, 2017

First Posted (Estimate)

February 2, 2017

Study Record Updates

Last Update Posted (Actual)

September 23, 2021

Last Update Submitted That Met QC Criteria

September 22, 2021

Last Verified

February 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Profound Multiple Intellectual Disabilities

Clinical Trials on Visual-behavioral Scale at day 1

Subscribe